A comprehensive view of new use. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

AstraZeneca and MSD’s Lynparza tablets combined with abiraterone and prednisone or prednisolone now approved in the EU for treatment of metastatic castration-resistant prostate cancer
Published: December 21, 2022 by AstraZeneca AB
GSK updates prescribing information for the ovarian cancer drug Zejula, limiting use to second-line maintenance therapy only to patients with certain mutation types; change was made at the request of FDA following review of Phase 3 clinical results
Published: November 14, 2022 by PharmaBiz (India)
Army’s testbed ISR business jets are opening doors to new mission possibilities
Published: September 06, 2022 by Breaking Defense
Moderna completes submission to the FDA requesting emergency use authorization for Omicron-targeting bivalent COVID-19 booster vaccine; application is for a booster dose in adults age 18 years and older
Published: August 26, 2022 by Moderna Inc.
FBSciences announces EPA approval of its FBS Defense 500 for fungicide and insecticide uses, in addition to previous approvals; product helps combat biological resistance by controlling nematodes, insects, and fungal diseases in one ingredient
Published: June 08, 2022 by PR Newswire

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count